Gyre Therapeutics (GYRE) Free Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) reported Free Cash Flow of $3.0 million for Q1 2026, up 1303.98% year-over-year from $215244.6 in Q1 2025, and up 152.61% on a QoQ basis from -$5.7 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Free Cash Flow data on file, last reported at $3.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 1303.98% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (up 134.8% YoY) and the FY2025 annual result came in at -$190000.0, up 96.81% from the prior year.
- Free Cash Flow advanced to $3.0 million in Q1 2026 per GYRE's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $42.3 million in Q4 2022 and bottomed at -$12.3 million in Q2 2022.
- The 5-year median for Free Cash Flow is $1.0 million (2023), against an average of $1.5 million.
- The widest annual swing landed in 2024, when Free Cash Flow slumped 437.99%; it then surged 1303.98% in 2026.
- Tracing GYRE's Free Cash Flow over 5 years: stood at $42.3 million in 2022, then sank by 97.55% to $1.0 million in 2023, then slumped by 359.94% to -$2.7 million in 2024, then tumbled by 113.29% to -$5.7 million in 2025, then soared by 152.61% to $3.0 million in 2026.
- Per Business Quant, the three latest GYRE Free Cash Flow figures stand at $3.0 million (Q1 2026), -$5.7 million (Q4 2025), and $3.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 3.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.02 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Sep 30, 2025 | 3.93 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | -251,000.00 |
| Mar 31, 2025 | -251,000.00 |
| Dec 31, 2024 | -2.69 Mn |
| Dec 31, 2024 | -2.69 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Jun 30, 2024 | -6.95 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 5.61 Mn |
| Sep 30, 2023 | 5.61 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | 8.68 Mn |
| Mar 31, 2023 | 8.68 Mn |
| Dec 31, 2022 | 42.30 Mn |
| Dec 31, 2022 | 42.30 Mn |
| Sep 30, 2022 | -7.28 Mn |
| Sep 30, 2022 | -7.28 Mn |
| Jun 30, 2022 | -12.29 Mn |
| Jun 30, 2022 | -12.29 Mn |
| Mar 31, 2022 | -12.05 Mn |
| Mar 31, 2022 | -12.05 Mn |
| Dec 31, 2021 | -17.68 Mn |
| Dec 31, 2021 | -17.68 Mn |
| Sep 30, 2021 | -22.09 Mn |
| Sep 30, 2021 | -22.09 Mn |
| Jun 30, 2021 | -20.12 Mn |
| Jun 30, 2021 | -20.12 Mn |
| Mar 31, 2021 | -24.36 Mn |
| Mar 31, 2021 | -24.36 Mn |
| Dec 31, 2020 | -22.11 Mn |
| Dec 31, 2020 | -22.11 Mn |
| Sep 30, 2020 | -13.20 Mn |
| Sep 30, 2020 | -13.20 Mn |
| Jun 30, 2020 | -15.15 Mn |
| Jun 30, 2020 | -15.15 Mn |
| Mar 31, 2020 | -4.81 Mn |
| Mar 31, 2020 | -4.81 Mn |
| Dec 31, 2019 | -8.09 Mn |
| Dec 31, 2019 | -8.09 Mn |
| Sep 30, 2019 | -9.10 Mn |
| Sep 30, 2019 | -9.10 Mn |
| Jun 30, 2019 | -11.52 Mn |
| Jun 30, 2019 | -11.52 Mn |
| Mar 31, 2019 | -14.97 Mn |
| Mar 31, 2019 | -14.97 Mn |
| Dec 31, 2018 | -9.19 Mn |
| Dec 31, 2018 | -9.19 Mn |
| Sep 30, 2018 | -7.02 Mn |
| Sep 30, 2018 | -7.02 Mn |
| Jun 30, 2018 | -7.42 Mn |
| Jun 30, 2018 | -7.42 Mn |
| Mar 31, 2018 | -5.31 Mn |
| Mar 31, 2018 | -5.31 Mn |
| Dec 31, 2017 | -6.34 Mn |
| Dec 31, 2017 | -6.34 Mn |
| Sep 30, 2017 | -4.93 Mn |
| Sep 30, 2017 | -4.93 Mn |
| Jun 30, 2017 | -4.40 Mn |
| Jun 30, 2017 | -4.40 Mn |
| Mar 31, 2017 | -4.30 Mn |
| Mar 31, 2017 | -4.30 Mn |
| Dec 31, 2016 | -5.10 Mn |
| Dec 31, 2016 | -5.10 Mn |
| Sep 30, 2016 | -5.13 Mn |
| Sep 30, 2016 | -5.13 Mn |
| Jun 30, 2016 | -3.88 Mn |
| Jun 30, 2016 | -3.88 Mn |
| Mar 31, 2016 | -4.83 Mn |
| Mar 31, 2016 | -4.83 Mn |
| Dec 31, 2015 | -5.24 Mn |
| Dec 31, 2015 | -5.24 Mn |
| Sep 30, 2015 | -9.63 Mn |
| Sep 30, 2015 | -9.63 Mn |
| Jun 30, 2015 | -1.37 Mn |
| Jun 30, 2015 | -1.37 Mn |
| Mar 31, 2015 | -2.98 Mn |
| Mar 31, 2015 | -2.98 Mn |
| Dec 31, 2014 | -2.06 Mn |
| Dec 31, 2014 | -2.06 Mn |
| Sep 30, 2014 | 19.43 Mn |
| Sep 30, 2014 | 19.43 Mn |
| Jun 30, 2014 | -8.91 Mn |
| Jun 30, 2014 | -8.91 Mn |
| Mar 31, 2014 | -14.85 Mn |
| Mar 31, 2014 | -14.85 Mn |
| Dec 31, 2013 | 23.22 Mn |
| Dec 31, 2013 | 23.22 Mn |
| Sep 30, 2013 | -9.71 Mn |
| Sep 30, 2013 | -9.71 Mn |
| Jun 30, 2013 | -10.44 Mn |
| Jun 30, 2013 | -10.44 Mn |
| Mar 31, 2013 | -9.39 Mn |
| Mar 31, 2013 | -9.39 Mn |
| Dec 31, 2012 | -11.80 Mn |
| Dec 31, 2012 | -11.80 Mn |
| Sep 30, 2012 | -10.40 Mn |
| Sep 30, 2012 | -10.40 Mn |
| Jun 30, 2012 | -17.43 Mn |
| Jun 30, 2012 | -17.43 Mn |
| Mar 31, 2012 | -24.95 Mn |
| Mar 31, 2012 | -24.95 Mn |
| Dec 31, 2011 | -20.78 Mn |
| Dec 31, 2011 | -20.78 Mn |
| Sep 30, 2011 | -18.25 Mn |
| Sep 30, 2011 | -18.25 Mn |
| Jun 30, 2011 | -23.48 Mn |
| Jun 30, 2011 | -23.48 Mn |
| Mar 31, 2011 | -22.64 Mn |
| Mar 31, 2011 | -22.64 Mn |
| Dec 31, 2010 | -17.33 Mn |
| Dec 31, 2010 | -17.33 Mn |
| Sep 30, 2010 | -17.19 Mn |
| Sep 30, 2010 | -17.19 Mn |